Inhibikase Therapeutics to provide trial update for Risvodetinib

Inhibikase Therapeutics announced that Dr. Milton Werner, President and Chief Executive Officer of Inhibikase Therapeutics, will present an update on the of the 201 Trial evaluating risvodetinib at the 2024 AD/PD Meeting being held March 5-9, 2024 in Lisbon, Portugal. “Parkinson’s disease remains one of the most prevalent neurodegenerative diseases worldwide, affecting more than a million people in the U.S. alone. The 201 Trial evaluating three doses of risvodetinib in untreated Parkinson’s patients is beginning to yield information about the experience of participants on risvodetinib,” said Dr. Werner. “While the trial is ongoing, we remain blinded to which participants are administered risvo. Fourteen percent of participants have reported a side effect that might be related to study drug and none of the reported side effects have been clinically meaningful. Moreover, participants’ experience in the trial appears to be positive. Twenty-five people have completed the 12 week dosing course and all have indicated interest to continue into the 12 month extension study when available.”